VIDEO: The Need for Clarity After Sandoz v. Amgen
by Ha Kung Wong
December 11, 2017
Ha Kung Wong, Amanda Forys, and Angus Worthing highlight unanswered questions surrounding the Supreme Court’s ruling in Sandoz v. Amgen, which reviewed procedural issues under the Biologics Price Competition and Innovation Act (BPCIA), as part of the The Center for Biosimilars™ Peer Exchange®.
Ha Kung Wong
has extensive experience litigating a wide variety of pharmaceutical cases, including those concerning biologics used to treat rheumatoid arthritis and autoimmune disorders. He also has extensive experience consulting, conducting due diligence and licensing pharmaceutical portfolios. Ha Kung has a B.S. in Biochemistry and a B.S. in Chemistry.